989PD - Phase 1b study of MEHD7945A (MEHD) plus cisplatin/fluorouracil (cis/5FU) or carboplatin/paclitaxel (carbo/pac) for 1st-line treatment of recurrent/...

Date 28 September 2014
Event ESMO 2014
Session Head and neck cancer
Topics Anti-Cancer Agents & Biologic Therapy
Cancer Immunology and Immunotherapy
Head and Neck Cancers
Presenter Paul Clement
Citation Annals of Oncology (2014) 25 (suppl_4): iv340-iv356. 10.1093/annonc/mdu340
Authors P.M. Clement1, J. Machiels2, L.J. Wirth3, P. Specenier4, T. Seiwert5, F. Mardjuadi2, X. Wang6, A. Kapp6, S. Royer-Joo7, E. Penuel6, B. McCall8, A. Pirzkall7, A. Jimeno9
  • 1General Medical Oncology, UZ Leuven University Hospital, 3000 - Leuven/BE
  • 2Oncology, Cancer Center, Service d’Oncologie Médicale, Cliniques Universitaires Saint-Luc and Institut de Recherche Clinique et Expérimentale (Pole MIRO), Université Catholique de Louvain, 1200 - Brussels/BE
  • 3Department Of Medicine, Massachusetts General Hospital, 02114 - Boston/US
  • 4Oncology, Universitair Ziekenhuis Antwerpen, Edegem/BE
  • 5Medicine, University of Chicago, Chicago/US
  • 6Research And Early Development, Genentech, Inc., South San Francisco/US
  • 7Oncology Early Clinical Development, Genentech, Inc., South San Francisco/US
  • 8Product Development, Oncology, Genentech, Inc., 94080 - South San Francisco/US
  • 9Medicine/oncology And Otolaryngology, University of Colorado School of Medicine, 80045 - Aurora/US



MEHD, a novel dual-action humanized IgG1 antibody that blocks ligand binding to HER3 and EGFR, inhibits signaling from ligand-dependent HER dimers. MEHD is active in multiple tumor models, including models resistant to anti-EGFR or anti-HER3, and enhances activity of chemotherapeutic agents. Single-agent activity in Phase 1a included confirmed PR in 2 RMSCCHN patients (pts) who had high levels of the HER3 ligand NRG1.


This open-label, multicenter, Phase 1b study with a modified 3 + 3 + 3 design assesses safety, PK and preliminary anti-tumor activity (RECIST v1.1) of MEHD plus platinum-based chemotherapy in 1st-line RMSCCHN pts. MEHD 1650 mg IV every 3 wks is combined with cis 100 mg/m2 / 5FU 1000 mg/m2/d on Days 1-4 (Arm A) or carbo (AUC 6 mg/mL·min) / pac 200 mg/m2 (Arm B) on Day 1 of 21-d cycles (up to 6), followed by MEHD maintenance until disease progression / intolerable toxicity. Mandatory tumor samples are assayed by qRT-PCR for biomarkers related to mechanism of action and SCCHN.


As of 28MAR14, 18 pts were treated and remain active: 6 ARM A pts have received 2-7 cycles (median 5.5) of MEHD; 13 Arm B pts have received 1-8 cycles (median 3.5). DLTs occurred in 2 pts in Arm A (1 G3 diarrhea, 1 G3 acute renal failure & G3 febrile neutropenia) and 1 pt in Arm B (G3 dehydration, anorexia). G ≥ 3 treatment-related AEs in ≥2 pts were hypokalemia (3), neutropenia (3), dehydration (3), fatigue (2), and hyponatremia (2) in Arm A and neutropenia (6), febrile neutropenia (3), and hyponatremia (2) in Arm B. Chemo dose was reduced in 9/18 pts. Preliminary MEHD PK in both arms was similar to single-agent MEHD profile. In 12 pts with on-treatment tumor assessments, best responses were 9 (75%) PR (4 confirmed) [Arm A: 4; Arm B: 5; HPV: 2 + , 5-, 2 unknown], and 3 (25%) stable disease [Arm A: 1; Arm B: 2]; after data cutoff 2 pts were reported with CR. Further biomarker data are pending.


MEHD plus cis/5FU or carbo/pac has been reasonably well tolerated with no new safety signals. G ≥ 3 AEs were manageable and less frequent post-Cycle 1. Both combinations had promising anti-tumor activity. Updated results will be presented.


T. Seiwert: Research funding; X. Wang, A. Kapp, S. Royer-Joo, E. Penuel, B. McCall and A. Pirzkall: Genentech employee. All other authors have declared no conflicts of interest.